Powell speech takes center stage in Tuesday’s economic events
TEANECK, N.J. - Phibro Animal Health Corporation (NASDAQ:PAHC), a $1.51 billion market cap company that has delivered an impressive 96% return over the past six months, has secured exclusive rights to develop and commercialize a new therapeutic compound for canine periodontal disease through a licensing agreement with Lighthouse Pharmaceuticals, Inc., according to a press release statement.According to InvestingPro data, Phibro maintains strong financial health with a current ratio of 2.76, indicating robust operational efficiency.
The agreement grants Phibro worldwide rights to develop, manufacture, and market Lighthouse Pharma’s proprietary compound specifically designed for periodontal care in dogs. The compound has shown promising results in preclinical efficacy and safety testing.
Under the terms of the agreement, Phibro will manage all regulatory approvals, commercial development, and global distribution efforts for the new therapy, utilizing its established veterinary market infrastructure.
Daniel Bendheim, Executive Vice President of Corporate Strategy at Phibro, noted that periodontal disease affects a majority of adult dogs and can lead to serious systemic health issues.
Laura Treml, Senior Vice President of Phibro’s Companion Animal Division, stated the compound could potentially transform veterinary management of periodontal disease in dogs.
The licensing deal represents a strategic expansion of Phibro’s companion animal portfolio, which has traditionally included products for livestock and other animals. The company’s stock is traded on the Nasdaq exchange.
Casey Lynch, CEO of Lighthouse Pharmaceuticals, said the agreement will enable continued development of the company’s gingipain inhibitor platform for additional applications.
Financial details of the licensing agreement were not disclosed in the announcement.
In other recent news, Phibro Animal Health Corporation reported impressive financial results for the fourth quarter of 2025. The company exceeded expectations with earnings per share of $0.57, surpassing the forecasted $0.52, and achieved revenue of $378.7 million, outperforming the anticipated $362.24 million. These results highlight the company’s strong performance and growth momentum. Following the earnings announcement, BNP Paribas Exane raised its price target for Phibro Animal Health to $37 from $24 while maintaining a Neutral rating. The research firm acknowledged the company’s robust revenue growth and margin expansion. Despite this positive outlook, BNP Paribas believes the current valuation accurately reflects Phibro’s prospects. These developments indicate a period of strong financial health and strategic positioning for Phibro Animal Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.